Dr. Mark Nathan Stein, MD

Dr. Stein practices at Columbia University Irving Medical Center in New York, New York.

Dr. Stein's NPI, 1568549319, was assigned on November 1, 2006. Dr. Stein graduated from New York Medical College in 1998. Dr. Stein's New York license number on file is 215813.

Dr. Stein's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 297-4255.

Dr. Stein's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Stein is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Stein to 2 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stein practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Stein's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Stein is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Stein's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists chronic anemia, fluid and electrolyte imbalances, lung cancer and prostate cancer among the conditions Dr. Stein treats.

CMS data shows 936 Medicare services from Dr. Stein across 6 procedure codes in 2024, for 226 Medicare patients. Medicare paid $126,638 for them.

CMS counts 226 Medicare patients who saw Dr. Stein in 2024. The largest group is 65 to 74, with 90 patients. 75% of them have cancer, and 75% have high blood pressure. 19% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Stein's median patient age at 75, with 9% women.

In 2024, Dr. Stein wrote 148 Medicare Part D claims for 48 patients. 85% of them were for generic drugs. CMS names the drug for 42 of them, across 3 drugs with 11 or more claims each, at $539 in total drug cost. In 2023, CMS named 34 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Stein for performance year 2024, reported through an alternative payment model (APM). Dr. Stein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Stein as offering telehealth.

Dmand AI links 166 papers to Dr. Stein, published from 2009 to 2025. 2016 was the busiest year, with 17. The most frequent topics are Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Antineoplastic Agents. Dr. Stein has published most often in Clin Cancer Res. Dr. Stein's most frequent co-authors are Robert S. Dipaola, Janice M. Mehnert and Michael Anthony Carducci, MD.

Dmand AI links Dr. Stein to 13 clinical trials, 6 of them phase 1 studies. 8 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 4. Open Payments lists research payments to Dr. Stein that name 1 trial.

CMS Open Payments shows 96 general payments to Dr. Stein from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Exelixis Inc. paid the most, $14,458. It also lists 9 research payments totaling $2,200 from 2020 to 2025, naming 1 clinical trial.

Dr. Stein graduated from New York Medical College in 1998. Dr. Stein is a member of ASCO.

Dr. Stein is in network with 11 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.